For most of Big Pharma, drug discounts have largely been about damage control. After months of tariff threats and talk of ...

The weight loss medicines are proving to be a test case for Robert F. Kennedy Jr., the health secretary, in straddling ...

Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have ...

The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.

Pfizer noted it has completed its acquisition of all outstanding shares of the company’s common stock for $65.60 per share in ...

Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, ...

The White House may have struck a deal with Eli Lilly and Novo Nordisk last week to lower the costs of their weight loss ...

Weight-loss drug developer Zealand Pharma said it halted work on an early-stage obesity treatment candidate to focus on more promising programs, including one for which it teamed up with Swiss giant ...

Pfizer has won a $10 billion deal to acquire obesity drug developer Metsera, securing foothold in lucrative weight-loss ...

A White House deal with Eli Lilly & Co. and Novo Nordisk to lower the prices of their popular obesity medicines, Zepbound and ...

The Trump administration is expected to announce deals with Eli Lilly and Novo Nordisk to cut prices of some weight loss ...

Eli Lilly and Novo Nordisk's competition in weight-loss drugs has affected thousands of jobs between Charlotte and Raleigh.